How to Cite
摘要
Кратком обзоре литературы освещены основные виды режимов мобилизации гемопоэтических стволовых клеток из костного мозга в периферическую кровь, а также способы получения трансплантата, содержащего как минимум субоптимальное количество CD34+клеток, для последующей аутологичной трансплантации гемопоэтических стволовых клеток больным множественной миеломой. Расширение спектра режимов мобилизации с выделением предикторов неудачной заготовки аутотрансплантата рассматривается как возможность индивидуального выбора наиболее эффективного режима мобилизации для больных множественной миеломой.
参考
Бессмельцев С.С., Абдулкадыров К.М. Множественная миелома: руководство для врачей. - М.: МК, 2016. - 512 с.
Менделеева Л.П., Вотякова О.М., Покровская О.С. и др. Национальные клинические рекомендации по диагностике и лечению множественной миеломы // Гематология и трансфузиология. - 2016. - №1. - Прил. 2. - С. 1-24.
Грицаев С.В., Кузяева А.А., Бессмельцев С.С. Отдельные аспекты трансплантации аутологичных гемопоэтических стволовых клеток больным множественной миеломой // Клиническая онкогематология. - 2017. - № 1. - С. 7-12.
Кострома И.И., Жернякова А.А., Чубукина Ж.В. и др. Заготовка гемопоэтических стволовых клеток у больных множественной миеломой: влияние леналидомида в индукционной терапии и режима мобилизации // Клиническая онкогематология. - 2018. - № 2. - С. 192-197.
Кострома И.И., жернякова А.А., Чубукина Ж.В. и др. Факторы, ассоциированные с эффективной заготовкой и приживлением аутотрансплантата у больных множественной миеломой // Клиническая онкогематология. - 2019. - С. 32-36.
Abrahamsen J.F, Stamnesfet S., Liseth K. et al. Large-volume leukapheresis yields more viable CD34 cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34 cells // Transfusion. - 2005. - Vol. 45. - P 248-253.
Abuabdou A., Rosenbaum E.R., Usmani S.Z. et al. Analysis of CD34 cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables // J. Clin. Apher. - 2014. - Vol. 29. - P. 251-255.
Anguita-Compagnon A.T., Dibarrart M.T., Palma J. et al. Mobilization and collection of peripheral blood stem cells: guidelines for blood volume to process, based on CD34-positive blood cell count in adults and children // Transplantat. Proc. - 2010. - Vol. 42. - P 339-344.
Attal M., Lauwers-Cances V., Hulin C. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma // N. Engl. J. Med. - 2017. - Vol. 376. - P 1311-1320.
Awan F., Kochuparambil S.T., Falconer A. et al. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies // Bone Marrow Transplant. - 2013. - Vol. 48. - P 1279-1284.
Bakanay S.M., Demirer T. Novel agents and approaches for stem cell mobilization in normal donors and patients // Bone Marrow Transplant. - 2012. - Vol. 47. - P 11541163.
Bhutani D., Zonder J., Valent J. et al. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma // Support Care Cancer. - 2013. - Vol. 21. - P 2437-2442.
Chow E., Rao K.V., Wood W.A. et l. Effectiveness of an algorithm-based approach to the utilization of plerixafor in patients undergoing chemotherapy-based stem cell mobilization // Biol Blood Marrow Transplant. - 2014. -Vol. 20. - P 1064-1068.
Cooper D.L., Pratt K., Baker J. et al. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution // Clin Lymphoma Myeloma. - 2011. - Vol. 11. - P. 267-272.
Costa L.J., Abbas J., Hogan K.R. et al. Growth factor plus preemptive (‘just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure // Bone Marrow Transplant. - 2012. - Vol. 47. - P 1403-1408.
Demirer T., Ayli M., Ozcan M. et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF // Br. J. Haematol. - 2002. - Vol. 116. - P 468474.
Desikan K.R., Jagannath S., Siegel D. et al. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma // Leuk. Lymphoma. - 1998. - Vol. 28. - P 501-508.
Fruehauf S., Ehninger G., Hubel K. et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients // Bone Marrow Transplant. - 2010. - Vol. 45. - P 269275.
Gambell P, Herbert K., Dickinson M. et al. Peripheral blood CD34 cell enumeration as a redictor of apheresis yield: an analysis of more than 1,000 collections // Biol Blood Marrow Transplant. - 2012. - Vol. 18. - P 763-772.
Gertz M.A. Current status of stem cell mobilization // Br J Haematol. -2010. - Vol. 150. - P 647-662.
Gertz M.A., Wolf R.C., Micallef I.N., Gastineau D.A. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma // Bone Marrow Transplant. - 2010. - Vol. 45. - P 1396-1403.
Giralt S., Costa L., Schriber J. et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations // Biol Blood Marrow Transplant. - 2014. - Vol. 20. - P. 295-308.
Hamadani M., Kochuparambil S.T., Osman S. et al. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies // Biol Blood Marrow Transplant. - 2012. - Vol. 18. -P. 11281135.
Harvey R.D., Kaufman J.L., Johnson H.R. et al. Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma // Biol Blood Marrow Transplant. - 2013. - Vol. 19. - P 1393-1411.
Hacioglu S., Sari I., Dogu M.H., Keskin A. The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF // Transfus Apher Sci. - 2014. - Vol. 50. - P 71-74.
Knudsen L.M., Rasmussen T., Nikolaisen K., Johnsen H.E. Mobilisation of tumour cells along with CD34 cells to peripheral blood in multiple myeloma // Eur J Haematol. -2001. - Vol. 67. - P 289-295.
Lemosa N.E., Farias M.G., Kubaski. Quantification of peripheral blood CD34 cells prior to stem cell harvesting by leukapheresis: a single center experience // Hematol. Transfus Cell Ther. - 2018. - Vol. 40. - P 213-218.
Lin T.L., Wang P.N., Kuo M.C. et al. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma // J Clin Apher. - 2016. - Vol. 31. - P 423428.
Mark T, Stern J., Furst J.R. et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma // Biol Blood Marrow Transplant. - 2008. - Vol. 14. - P 795-798.
Mateos M.V., Ludwig H., Bazarbachi A. et al. Insights on multiple myeloma treatment strategies // HemaSphere. -2018. - № 2. - P 1.
Micallef I.N.M., Ho A.D., Klein L.M. et al. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide // Bone Marrow Transplant. - 2011. - Vol. 46. - P 350-355.
Milone G., Martino M., spadaro A. et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs // Br J Haematol. - 2014. - Vol. 164. - P 113-123.
Mitterer M., Hirber J., Gentilini I. et al. Target value tailored (TVT) apheresis approach for blood progenitor cell collection after high-dose chemotherapy and rh-G-CSF // Bone Marrow Transplant. - 1996. - Vol. 18. - P 611-617.
Musto P, Simeon V., Grossi A. et al. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell Adulto Multiple Myeloma Working Party study // Stem Cell Res Ther. - 2015. - Vol. 6. - P 64.
Nademanee A.P, DiPersio J.F., Maziarz R.T. et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34( ) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34( ) cell count: results of a subset analysis of a randomized trial // Biol Blood Marrow Transplant. - 2012. - Vol. 18. - P 1564-1572.
Narayanasami U., Kanteti R., Morelli J. et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation // Blood. - 2001. - Vol. 98. - P 2059-2064.
Olivieri A., Marchetti M., Lemoli R. et al. Proposed definition of ‘poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo osseo // Bone Marrow Transplant. - 2012. - Vol. 47. - P 342-351.
Ozsan G.H., Micallef I.N., Dispenzieri A. et al. Hematopoietic recovery kinetics predicts for poor CD34 cell mobilization after cyclophosphamide chemotherapy in multiple myeloma // Am J Hematol. - 2012. - Vol. 87. - P 1-4.
Russell N., Douglas K., Ho A.D. et al. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective trial PREDICT // Haematologica. - 2013. -Vol. 98. - P 172-178.
Sheppard D., Tay J., Palmer D. et al. Improved prediction of CD34 cell yield before peripheral blood hematopoietic progenitor cell collection using a modi ed target value-tailored approach // Biol Blood Marrow Transplant. -2016. - Vol. 22. - P 759-775.
Shi P.A., Miller L.K., Isola L.M. Prospective study of mobilization kinetics up to 18 hours after late afternoon dosing of plerixafor // Transfusion. - 2014. - Vol. 54. - P 1263-1268.
Stewart D.A., Smith C., MacFarland R., Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma // Biol Blood Marrow Transplant. - 2009. - Vol. 15. - P 39-46.
Stover J., Shaw J.R., Kuchibhatla M. et al. Evaluation of hematopoietic stem Cell mobilization rates with early plerixafor administration for adult stem cell transplantation // Biol Blood Marrow Transplant. - 2017. - Vol. 23. - P 1290-1294.
Tuchman S.A., Bacon W.A., Huang L.W. et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma // J Clin Apher. -2015. - Vol. 30. - P 176-182.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019